Return-Path: <info@seet-sa.net>
Delivered-To: govancoz@zacp120.webway.host
Received: from zacp120.webway.host
	by zacp120.webway.host with LMTP
	id qPRnCtBH4GiKojwA8rC0kQ
	(envelope-from <info@seet-sa.net>)
	for <govancoz@zacp120.webway.host>; Sat, 04 Oct 2025 00:01:52 +0200
Return-path: <info@seet-sa.net>
Envelope-to: recep@govan.co.za
Delivery-date: Sat, 04 Oct 2025 00:01:52 +0200
Received: from vps54286.alfahosting-vps.de ([89.22.121.78]:43581)
	by zacp120.webway.host with esmtps  (TLS1.3) tls TLS_AES_256_GCM_SHA384
	(Exim 4.98.2)
	(envelope-from <info@seet-sa.net>)
	id 1v4nqa-0000000GhWl-0Zdp
	for recep@govan.co.za;
	Sat, 04 Oct 2025 00:01:51 +0200
Received: from ws-dip-gc02.diplomat.com.mt (c155-179.i01-7.onvol.net [212.56.155.179])
	by vps54286.alfahosting-vps.de (Postfix) with ESMTPA id 622E21BF736;
	Fri,  3 Oct 2025 17:13:47 +0000 (UTC)
Authentication-Results: vps54286.alfahosting-vps.de;
        spf=pass (sender IP is 212.56.155.179) smtp.mailfrom=info@seet-sa.net smtp.helo=ws-dip-gc02.diplomat.com.mt
Received-SPF: pass (vps54286.alfahosting-vps.de: connection is authenticated)
Content-Type: multipart/alternative; boundary="===============1090994829=="
MIME-Version: 1.0
Subject: Proposal for Strategic Business Collaboration.
To: Recipients <info@seet-sa.net>
From: "Dr. Shingo Iwamoto" <info@seet-sa.net>
Date: Fri, 03 Oct 2025 19:13:40 +0200
Reply-To: drshingoiwamotopharm1@gmail.com
X-Spam-Status: No, score=2.0
X-Spam-Score: 20
X-Spam-Bar: ++
X-Ham-Report: =?ISO-8859-1?Q?Spam_detection_software=2C_running_on_the_system_=22zacp120=2Ewebway?= =?ISO-8859-1?Q?=2Ehost=22=2C=0A_has_NOT_identified_this_incoming_ema?= =?ISO-8859-1?Q?il_as_spam=2E__The_original=0A_message_has_been_attac?= =?ISO-8859-1?Q?hed_to_this_so_you_can_view_it_or_label=0A_similar_fu?= =?ISO-8859-1?Q?ture_email=2E__If_you_have_any_questions=2C_see=0A_ro?= =?ISO-8859-1?Q?ot=5C=40localhost_for_details=2E=0A_Content_preview=3A_?= =?ISO-8859-1?Q?_Dear_Esteemed_Professional=2C_I_hope_this_message_fi?= =?ISO-8859-1?Q?nds_you=0A___well=2E_Nichi-Iko_Pharmaceutical_Co=2E=2C?= =?ISO-8859-1?Q?_Ltd=2E=2C_a_leading_pharmaceutical_manufacturer=0A__?= =?ISO-8859-1?Q?__based_in_Japan=2C_is_currently_seeking_a_qualified_?= =?ISO-8859-1?Q?individual_to_=5B=2E=2E=2E=5D_=0A_Content_analysis_de?= =?ISO-8859-1?Q?tails=3A___=282=2E0_points=2C_5=2E0_required=29=0A__p?= =?ISO-8859-1?Q?ts_rule_name______________description=0A_----_-------?= =?ISO-8859-1?Q?---------------_-------------------------------------?= =?ISO-8859-1?Q?-------------=0A_-0=2E0_SPF=5FPASS_______________SPF=3A_?= =?ISO-8859-1?Q?sender_matches_SPF_record=0A__0=2E2_FREEMAIL=5FREPLYT?= =?ISO-8859-1?Q?O=5FEND=5FDIGIT_Reply-To_freemail_username_ends_in_di?= =?ISO-8859-1?Q?git=0A_____________________________=5Bdrshingoiwamoto?= =?ISO-8859-1?Q?pharm1=28at=29gmail=2Ecom=5D=0A__0=2E0_RCVD=5FIN=5FVA?= =?ISO-8859-1?Q?LIDITY=5FCERTIFIED=5FBLOCKED_RBL=3A_ADMINISTRATOR_NOT?= =?ISO-8859-1?Q?ICE=3A_The=0A_____________________________query_to_Va?= =?ISO-8859-1?Q?lidity_was_blocked=2E__See=0A________________________?= =?ISO-8859-1?Q?_____https=3A//knowledge=2Evalidity=2Ecom/hc/en-us/ar?= =?ISO-8859-1?Q?ticles/20961730681243=0A_____________________________?= =?ISO-8859-1?Q?_for_more_information=2E=0A__________________________?= =?ISO-8859-1?Q?_=5B89=2E22=2E121=2E78_listed_in_sa-trusted=2Ebondeds?= =?ISO-8859-1?Q?ender=2Eorg=5D=0A__0=2E0_RCVD=5FIN=5FVALIDITY=5FRPBL=5FB?= =?ISO-8859-1?Q?LOCKED_RBL=3A_ADMINISTRATOR_NOTICE=3A_The_query_to=0A_?= =?ISO-8859-1?Q?_____________________________Validity_was_blocked=2E_?= =?ISO-8859-1?Q?_See=0A_____________________________https=3A//knowled?= =?ISO-8859-1?Q?ge=2Evalidity=2Ecom/hc/en-us/articles/20961730681243=0A_?= =?ISO-8859-1?Q?_____________________________for_more_information=2E=0A?= =?ISO-8859-1?Q?_____________________________=5B89=2E22=2E121=2E78_li?= =?ISO-8859-1?Q?sted_in_bl=2Escore=2Esenderscore=2Ecom=5D=0A__0=2E0_R?= =?ISO-8859-1?Q?CVD=5FIN=5FVALIDITY=5FSAFE=5FBLOCKED_RBL=3A_ADMINISTR?= =?ISO-8859-1?Q?ATOR_NOTICE=3A_The_query_to=0A_______________________?= =?ISO-8859-1?Q?_______Validity_was_blocked=2E__See=0A_______________?= =?ISO-8859-1?Q?______________https=3A//knowledge=2Evalidity=2Ecom/hc?= =?ISO-8859-1?Q?/en-us/articles/20961730681243=0A____________________?= =?ISO-8859-1?Q?__________for_more_information=2E=0A_________________?= =?ISO-8859-1?Q?____________=5B89=2E22=2E121=2E78_listed_in_sa-accred?= =?ISO-8859-1?Q?it=2Ehabeas=2Ecom=5D=0A__0=2E0_HTML=5FMESSAGE________?= =?ISO-8859-1?Q?___BODY=3A_HTML_included_in_message=0A__0=2E0_KAM=5FD?= =?ISO-8859-1?Q?MARC=5FSTATUS_______Test_Rule_for_DKIM_or_SPF_Failure?= =?ISO-8859-1?Q?_with_Strict=0A_____________________________Alignment?= =?ISO-8859-1?Q?=0A__1=2E8_FREEMAIL=5FFORGED=5FREPLYTO_Freemail_in_Re?= =?ISO-8859-1?Q?ply-To=2C_but_not_From?=
X-Spam-Flag: NO

You will not see this in a MIME-aware mail reader.
--===============1090994829==
Content-Type: text/plain; charset="iso-8859-1"
MIME-Version: 1.0
Content-Transfer-Encoding: quoted-printable
Content-Description: Mail message body

Dear Esteemed Professional,
 I hope this message finds you well.
 Nichi-Iko Pharmaceutical Co., Ltd., a leading pharmaceutical manufacturer =
based in Japan, is currently seeking a qualified individual to serve as our=
 official representative in South Africa. This role involves managing miner=
al procurement and overseeing the establishment of our annex office in Sout=
h Africa under a five-year contractual agreement.
 This is a strategic opportunity to represent a respected global brand and =
play a key role in expanding our international presence. We are offering a =
competitive compensation package along with decision-making autonomy.
 If you are interested in learning more, kindly respond to this message for=
 further details.
 Warm regards,
Dr. Shingo Iwamoto
President & CEO
Nichi-Iko Pharmaceutical Co., Ltd.
5-4 Nihonbashi-Honcho 1-chome, Chuo-ku, Tokyo, Japan

--===============1090994829==
Content-Type: text/html; charset="iso-8859-1"
MIME-Version: 1.0
Content-Transfer-Encoding: quoted-printable
Content-Description: Mail message body

<HTML><head><meta http-equiv=3D"Content-Type" content=3D"text/html; charset=
=3Diso-8859-1"/></head><BODY><P>Dear Esteemed Professional,</P>
<P>I hope this message finds you well.</P>
<P>Nichi-Iko Pharmaceutical Co., Ltd., a leading pharmaceutical manufacture=
r based in Japan, is currently seeking a qualified individual to serve as o=
ur official representative in South Africa. This role involves managing min=
eral procurement and overseeing the establishment of our annex office in So=
uth Africa under a five-year contractual agreement.</P>
<P>This is a strategic opportunity to represent a respected global brand an=
d play a key role in expanding our international presence. We are offering =
a competitive compensation package along with decision-making autonomy.</P>
<P>If you are interested in learning more, kindly respond to this message f=
or further details.</P>
<P>Warm regards,<BR>Dr. Shingo Iwamoto<BR>President &amp; CEO<BR>Nichi-Iko =
Pharmaceutical Co., Ltd.<BR>5-4 Nihonbashi-Honcho 1-chome, Chuo-ku, Tokyo, =
Japan</P></BODY></HTML>
--===============1090994829==--